Association of antiretroviral therapy with fibrinogen levels in HIV-infection

AIDS

Volumn 22, Issue 6, 2008, Pages 707-715

  Madden, Erin ^a   Lee, Grace ^b,c   Kotler, Donald P ^d   Wanke, Christine ^e   Lewis, Cora E ^f   Tracy, Russell ^g   Heymsfield, Steven ^h   Shlipak, Michael G ^a,b,c   Bacchetti, Peter ^b   Scherzer, Rebecca ^a   Grunfeld, Carl ^a,b,c  

^a NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d New York Presbyterian Columbia University Medical Center   (United States)

^e TUFTS UNIVERSITY   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF VERMONT   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Fibrinogen; HIV; Nonnucleoside reverse transcriptase inhibitors; Protease inhibitors

Indexed keywords

AMPRENAVIR; C REACTIVE PROTEIN; DELAVIRDINE; EFAVIRENZ; FIBRINOGEN; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; CARDIAC PATIENT; CARDIOVASCULAR RISK; CONTROL GROUP; CORONARY ARTERY DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LINEAR REGRESSION ANALYSIS; PROTEIN EXPRESSION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CASE-CONTROL STUDIES; FEMALE; FIBRINOGEN; HIV INFECTIONS; HUMANS; INDINAVIR; LINEAR MODELS; MALE; NEVIRAPINE; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR;

EID: 41349122933     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f560d9     Document Type: Article

References (28)

1. Currier JS, Taylor A, Boyd F, Dezii CM, Kkawabata H, Burtcel B, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506-512.
2. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30:471-477.
3. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
4. Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, et al. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS 2006; 20:1941-1950.
5. Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005; 40:1215-1220.
6. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol 1999; 10:435-441.
7. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294:1799-1809.
8. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29:441-449.
9. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-F70.
10. Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-131.
11. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006; 42:562-571.
12. Alessi MC, Lijnen HR, Bastelica D, Juhan-Vague I. Adipose tissue and atherothrombosis. Pathophysiol Haemost Thromb 2003; 33:290-297.
13. Bo M, Raspo S, Morra F, Cassader M, Isaia G, Poli L. Body fat is the main predictor of fibrinogen levels in healthy nonobese men. Metabolism 2004; 53:984-988.
14. Piche ME, Lemieux S, Weisnagel SJ, Corneau L, Nadeau A, Bergeron J. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol 2005; 96:92-97.
15. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41:1105-1116.
16. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol 2006; 163:860-869.
17. Gallagher D, Belmonte D, Deurenberg P, Wang Z, Krasnow N, Pi-Sunyer FX, Heymsfield SB. Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol 1998; 275:E249-E258.
18. Hastie T, Tibshirani RJ. Generalized additive models. New York: Chapman and Hall; 1990.
19. Efron B, Tibshirani R. An introduction to the boostrap. London: Chapman and Hall; 1993.
20. Lee G, Lo JC, Aweeka F, Schwarz J-M, Mulligan K, Schambelan M, Grunfeld C. Single-dose lopinavir/ritonavir acutely inhibits insulin-mediated glucose disposal in healthy normal volunteers. Clin Infect Dis 2006; 43:658-660.
21. Lee G, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, Schambelan M, Grunfeld C. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS 2007; 21:2183-2190.
22. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004; 18:641-649.
23. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-F18.
24. Noor MA, Parker RA, O'Mara E, Grasela DM, Currie A, Hodder SL, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137-2144.
25. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813-1821.
26. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, et al. Effect of ritonavir on lipids and postheparin lipase activities in normal subjects. AIDS 2000; 14:51-57.
27. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258:1183-1186.
28. Reingold JS, Wanke C, Kotler DP, Lewis CE, Tracy R, Heymsfield S, Tien PC, Bacchetti P, Scherzer R, Grunfeld C, Shlipak MG. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: The FRAM Study. JAIDS 2008 in press.